New funds will support ongoing commercial activities in Europe, the U.S and Asia and further enhance the development of a next-generation single-cell cloning platform.
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy.